Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna - General Hospital, Vienna, Austria.
Department of Pathology, Medical University of Vienna - General Hospital, Vienna, Austria.
In Vivo. 2021 Jan-Feb;35(1):385-391. doi: 10.21873/invivo.12269.
BACKGROUND/AIM: Ewing sarcoma (ES) and osteosarcomas (OSA) are the most common bone tumor types in adolescents and young adults (AYA). Therapy management of these tumors consists of preoperative chemotherapy, operation, and postoperative chemotherapy. The aim of this study was to evaluate the efficacy and tolerability of EURAMOS-A and EURO E.W.I.N.G. protocols.
We retrospectively evaluated 31 patients between 18 and 39 years of age with ES and OSA treated at the Department of Medicine I, Clinical Division of Oncology. Patients with ES were treated according the EURO E.W.I.N.G protocol, whereas patients with OSA according to the EURAMOS-1 protocol.
Most frequent tumor sites for ES were thorax and pelvis, each 33%. Eight patients had initially localized disease (67%). A median of 3 cycles of full dose chemotherapy could be administered. Nine patients had a dose reduction (75%). Most common reason for dose reduction was prolonged aplasia (67%). Overall response rate (ORR) was 33%. For OSA patients, the most frequent tumor site was the lower extremity (58%). Sixteen patients (84%) had initially localized disease. A median of only 9 cycles of EURAMOS-1 in full dose could be administered. Most common reason for dose reduction was elevated methotrexate level (53%) and ORR was 90%.
The two studied protocols were well-tolerated in the AYA patients included in this study. Dose reductions instead of dose delays should be considered when side effects occur.
背景/目的：尤文肉瘤（ES）和骨肉瘤（OSA）是青少年和年轻成人（AYA）中最常见的骨肿瘤类型。这些肿瘤的治疗管理包括术前化疗、手术和术后化疗。本研究的目的是评估 EURAMOS-A 和 EURO E.W.I.N.G. 方案的疗效和耐受性。
我们回顾性评估了在医学 I 系临床肿瘤学分部接受治疗的 31 名年龄在 18 至 39 岁之间的 ES 和 OSA 患者。ES 患者根据 EURO E.W.I.N.G. 方案治疗，而 OSA 患者根据 EURAMOS-1 方案治疗。
ES 最常见的肿瘤部位是胸部和骨盆，各占 33%。8 名患者最初患有局限性疾病（67%）。中位数接受了 3 个周期的全剂量化疗。9 名患者减少了剂量（75%）。减少剂量的最常见原因是延长再生障碍（67%）。总缓解率（ORR）为 33%。对于 OSA 患者，最常见的肿瘤部位是下肢（58%）。16 名患者（84%）最初患有局限性疾病。中位数仅接受了 9 个周期的 EURAMOS-1 全剂量化疗。减少剂量的最常见原因是甲氨蝶呤水平升高（53%），ORR 为 90%。
在本研究中纳入的 AYA 患者中，这两种研究方案的耐受性良好。当出现副作用时，应考虑减少剂量而不是延迟剂量。
